Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs

Multiple myeloma is characterized by increased bone marrow neovascularization driven in part by vascular endothelial growth factor (VEGF). In addition, the Ras/Raf/MEK/ERK pathway is critical for the proliferation of myeloma cells and is often upregulated. Sorafenib (Nexavar) is a novel multi-kinase...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Ramakrishnan, V, Timm, M, Haug, JL, Kimlinger, TK, Wellik, LE, Witzig, TE, Rajkumar, SV, Adjei, AA, Kumar, S
Formato: Artigo
Idioma:Inglês
Publicado: 2009
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC2908017/
https://ncbi.nlm.nih.gov/pubmed/19935717
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/onc.2009.403
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares